Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

Biogen Idec building

Biogen buys into Rodin’s Alzheimer’s candidate

And may acquire the epigenetics-focused Massachusetts firm

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

- PMLiVE

GSK earns expanded approval for Volibris in Europe

Additional indication given to pulmonary arterial hypertension drug

- PMLiVE

GSK and AZ drugs impress in lupus trials

Raises hope for better treatment for debilitating disease

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Axovant takes Alzheimer’s drug into phase III

Aims to bring first treatment in a decade to market

Is Technology Harming Your Brain?

Is technology harming your brain? Saycomms healthcare PR team confronts different opinions on how technology affects memories and attention span.

Say Communications

- PMLiVE

GSK’s Breo fails to show survival benefit in COPD

Comes as GSK sees continued slump in sales

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links